Is Nuvalent, Inc. (NUVL) a Buy, Sell, or Hold?
NASDAQ : NUVL
Nuvalent, Inc.
$123.96 USD
$0 (0.0%)
- Volume
- 0
- Average Volume
- 2.33M
- Market Capitalization
- $9.13B
- P/E Ratio
- -20.46
- Dividend Yield
- 0.00%
- Price Target
- $124.00
- Year High
- $123.99
- Year Low
- $71.13
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $16.14
Company Overview
NASDAQ
James R. Porter
Biotechnology
Healthcare
NUVL
234
US
USD
Liquidity Metrics
0.00
16.14
16.14
1.97
0.00
Sales & Valuation
-$
0.00
8.30
-29.21
-3.98
Profitability
-$5.85
-$425.38M
0.00%
0.00%
-42.78%
-33.81%
P/E Metrics
-20.46
0.69
0.69
Analyst Price Target & Rating
$124.00
$165.00
$122.85
0/5
19 Analysts
-0.03%
Financial Health Scores
33.85
2/9
$1.23B
$1.33B
$156.78M
-$436.61M
Key Metrics (TTM)
$8.98B
0.00
-26.84
16.14
-42.78%
-35.11%
-4.62%
-3.42%
0 days
Company Executives
| Name | Title |
|---|---|
| Deborah Ann Miller | Chief Legal Officer & Secretary |
| Henry Pelish | Chief Scientific Officer |
| Chelcie Lister | Senior Director of Investor Relations & Corporate Communications |
| Benjamin Lane | Chief Technical Operations Officer |
| James R. Porter | Chief Executive Officer, President & Director |
| Joshua Horan | Senior Vice President of Chemistry |
| Alex Balcom | Chief Financial Officer & Treasurer |
| John Soglia | Senior Vice President of Translational Development |
| Ruth Adams | Senior Vice President of Clinical Operations |
| Darlene Noci | Chief Development Officer |
| Christopher D. Turner | Chief Medical Officer |
Poll Results
No votes yet today — be the first to share your view!
About Nuvalent, Inc. (NASDAQ:NUVL) Stock
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhib ... itors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Fifth Third Bancorp Acquires New Holdings in Nuvalent, Inc. $NUVL
2026-07-22 03:47:48
Fifth Third Bancorp bought a new position in shares of Nuvalent, Inc. (NASDAQ: NUVL) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 23,621 shares of the company's stock, valued at approximately $2,420,000. Other institutional investors and hedge funds
2026-07-21 10:46:00
BALA CYNWYD, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
2026-07-16 10:26:00
BALA CYNWYD, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
2026-07-13 14:00:00
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propo
2026-07-13 13:29:00
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nuvalent, Inc. (NasdaqGS: NUVL) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Nuvalent will receive $124.00 in cash for each share of Nuvalent that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate.
2026-07-02 05:08:00
MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Nuvalent (NASDAQ: NUVL) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with GSK plc.
2026-06-30 13:16:00
BALA CYNWYD, Pa., June 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders?
2026-06-25 13:00:00
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026
Frequently Asked Questions
-
What is the current Nuvalent, Inc. (NUVL) stock price?
-
Nuvalent, Inc.(NASDAQ:NUVL) stock price is $123.96 in the last trading session. During the trading session, NUVL stock reached the peak price of $123.99 while $71.13 was the lowest point it dropped to. The percentage change in NUVL stock occurred in the recent session was 0.0% while the dollar amount for the price change in NUVL stock was $0.
-
NUVL's industry and sector of operation?
-
The NASDAQ listed NUVL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of NUVL?
-
Deborah Ann Miller | Chief Legal Officer & Secretary
Henry Pelish | Chief Scientific Officer
Chelcie Lister | Senior Director of Investor Relations & Corporate Communications
Benjamin Lane | Chief Technical Operations Officer
James R. Porter | Chief Executive Officer, President & Director -
How many employees does NUVL have?
-
Number of NUVL employees currently stands at 234. NUVL operates from One Broadway, Cambridge, MA 02142, US.
-
Link for NUVL official website?
-
Official Website of NUVL is: https://www.nuvalent.com
-
How do I contact NUVL?
-
NUVL could be contacted at phone #857 357 7000 and can also be accessed through its website. NUVL operates from One Broadway, Cambridge, MA 02142, US.
-
How many shares of NUVL are traded daily?
-
The average number of NUVL shares traded daily for last 3 months was 2.33M.
-
What is the market cap of NUVL currently?
-
The market value of NUVL currently stands at $9.13B with its latest stock price at $123.96